Platinum-containing doublet chemotherapy

Author: iuun

August undefined, 2024

WebbPlatinum-doublet chemotherapy as second-line treatment for patients with relapsed small-cell lung cancer can be considered as a reasonable option in comparison with non … WebbA Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naive Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer ... Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy Y https: ...

ESMO Asia Congress OncologyPRO

Webb332P - A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from ... a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, showed promising antitumor efficacy in advanced ... WebbAlthough first-line platinum-containing chemotherapy results in objective responses or stable disease in approximately 65–75% of patients, ... first-line systemic therapy for patients with locally advanced or metastatic UC has consisted of platinum-doublet chemotherapy. Beyond chemotherapy, several antiangiogenic agents (bevacizumab ... brain injury attorney brooklyn ny

A comparison between triplet and doublet chemotherapy in …

Webbplatinum-containing chemotherapy on the same day Use separate infusion bags and filters for each infusion Do not coadminister other drugs through the same IV line Flush the entire IV line at the end of infusion YERVOY Do not shake product Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. Webb15 maj 2024 · The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by … WebbThe platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events). In total, a cancer patient can experience any combination of around 40 specific side effects. hackthebox active directory

The side effects of platinum-based chemotherapy drugs: a review …

Webb3 juni 2024 · Platinum-containing doublet chemotherapy is generally regarded as the standard first-line treatment for patients with RMNPC. The randomized phase III trial of gemcitabine and cisplatin (GC) versus 5-fluorouracil and cisplatin (PF) in RMNPC established GC as the standard of care first-line regimen. Webb7 maj 2024 · Bevacizumab plus pemetrexed–platinum doublet chemotherapy has become a standard first-line treatment for advanced lung adenocarcinoma patients with negative results of detecting PD-L1 expression, EGFR mutations, and ALK/ROS1 gene fusions, or after the failure of targeted therapies for patients with EGFR mutations or ALK/ROS1 … hack the box agileWebbTriple chemotherapy containing platinum (TP, combination of cisplatin, etoposide, and irinotecan) was associated with favorable ORR (intravenous topotecan vs TP; odds ratio: 0.13, ... The rechallenge of the platinum doublet is … hackthebox appointment

"Webb7 okt. 2024 · Background: Platinum-containing doublet chemotherapy regimens are generally considered the standard first-line systemic therapy for recurrent or … " - Platinum-containing doublet chemotherapy

Platinum-containing doublet chemotherapy

NSCLC, long-term survival with neoadjuvant immunotherapy

Webb1 maj 2024 · In patients with recurrent ovarian cancer suitable for platinum-based re-treatment, the approved chemotherapy regimens for use in combination with bevacizumab are gemcitabine–carboplatin (based on the OCEANS trial) and paclitaxel–carboplatin (based on the GOG-0213 trial). Webbför 2 dagar sedan · The type of platinum-containing doublet chemotherapy was selected by investigators according to treatment practices of therapeutic institutions—paclitaxel in combination with cisplatin was given to patients with squamous NSCLC, while pemetrexed in combination with cisplatin was given to patients with non-squamous NSCLC.

Did you know?

Webb7 mars 2016 · This non-platinum–containing chemotherapy regimen including bevacizumab met the study-specified definition of effectiveness and improved symptoms of lung cancers. The toxicities were comparable to those in phase II experiences with platinum doublet regimens plus bevacizumab. Webb12 apr. 2024 · The type of platinum-containing doublet chemotherapy was selected by investigators according to treatment practices of therapeutic institutions—paclitaxel in combination with cisplatin was given...

Webb13 apr. 2024 · Triple-negative breast cancer (TNBC) is the most aggressive and lethal breast cancer (BC) subtype. 1 Chemotherapy still represents the backbone of the first-line treatment for patients with advanced TNBC (aTNBC). In patients with programmed death-ligand 1 (PD-L1)-negative aTNBC, single-agent or combination chemotherapy represents … Webb11 okt. 2010 · A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum-Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung (FLAIR) Actual Study Start Date : June 27, 2011: Actual Primary Completion Date :

Webb29 apr. 2024 · For those patients who have not received an immune checkpoint inhibitor as first-line therapy, or who experience recurrence within 6 months of platinum-containing chemoradiation, both pembrolizumab and another PD-1 inhibitor, nivolumab, improve survival compared with investigators’ choice chemotherapy. 15,16 In the EAGLE trial, the … Webb1 mars 2008 · A platinum-taxane doublet has been established as the standard of care in the initial chemotherapy for ovarian cancer. Treatment at relapse is based largely on the platinum-free interval (PFI). Women with a PFI of 6–12 months are said to be partially platinum-sensitive.

WebbIn IMpower110 (NCT02409342), 1L atezo (anti–PD-L1) improved OS vs platinum-doublet chemo (PDC) in pts with PD-L1–high NSCLC and ECOG PS ≤1. However, ≥40% of NSCLC pts have poor ECOG PS (≥2) and/or substantial comorbidities, resulting in ineligibility for platinum-based chemo and most 1L clinical trials. IPSOS is a global, multicenter, open …

WebbThe phase 3 trial Check-Mate 816 evaluated the efficacy and safety of neoadjuvant Nivolumab plus platinum doublet chemotherapy (three cycles) as compared with platinum doublet chemotherapy alone (three cycles), before definitive surgery, in patients with resectable NSCLC, stage IB (≥4 cm) to IIIA (AJCC 7th edition), without known ALK … brain injury association of florida biafWebb16 apr. 2024 · Management of newly diagnosed ovarian cancer typically involves cytoreductive surgery and platinum–taxane doublet chemotherapy. At relapse, patients might be candidates for platinum re-treatment, depending on several factors, including previous response and the interval since completing platinum-containing therapy. brain injury attorney clark countyWebb13 nov. 2024 · Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer. Advanced non-small cell lung cancer in elderly patients can … hackthebox acute walkthroughWebbplatinum-based doublet chemotherapy) and progressed are eligible. However, subjects who received a tyrosine kinase inhibitor after failure of a prior platinum-based therapy … brain injury attorney cincinnatiWebb15 apr. 2016 · Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC … hack the box arcticWebbPlatinum‑containing doublet chemotherapy is the cornerstone of lung cancer treatment; however, cisplatin resistance is a major obstacle in the treatment of lung cancer. … brain injury attorney clevelandWebbför 2 dagar sedan · According to results presented at the European Lung Cancer Congress 2024 (Copenhagen, 29 March–1 April), long-term analysis of the phase III CheckMate 816 trial (at a median follow-up of 41.4 months) demonstrated that neoadjuvant nivolumab plus platinum doublet chemotherapy prolonged event-free survival (EFS) compared with … brain injury attorney hancock county